All active operations have been stopped after failure of the Hemoximer Phase III clinical study. CU-2010, another product candidate had been licensed to ‚The Medicines Company‘ (TMC). TMC is further developing CU-2010 and will pay milestones and royalties to Curacyte upon further development success and after possible approval. In August 2012 Curacyte has participated in Wilex capital increase. With € 8,5 Mio. invested Curacyte holds 7,3% of Wilex today.